NFE2L2和SLC25A39通过GSH新陈代谢驱动了cuproptosis抵抗
Jiao Liu1, Hu Tang2, Fangquan Chen2
1DAMP Laboratory, The Third Affiliated Hospital, Guangzhou Medical University, Guangzhou, 510150, Guangdong, China. 2018683073@gzhmu.edu.cn.
谷氨通过在胰腺癌细胞中结合铜来抑制细胞死亡途径cuproptosis. 准NFE2L2-GSH-SLC25A39通路可能会抑制瘤生长.
科学领域:
- 细胞生物学 细胞生物学
- 生物化学 生物化学
- 在瘤学瘤学.
背景情况:
- 质亡是一种受调节的细胞死亡途径,由线粒体铜过载和蛋白质毒性驱动.
- 胰腺管腺癌 (PDAC) 是一个重大的治疗挑战.
研究的目的:
- 研究谷氨 (GSH) 作为PDAC中cuproptosis的调节者的作用.
- 阐明GSH抑制cuproptosis背后的分子机制.
- 探索针对NFE2L2-GSH-SLC25A39通路进行PDAC治疗的治疗策略.
主要方法:
- 研究了GSH在PDAC细胞系中对cuproptosis的影响.
- 使用elasclomol加铜 (ES-Cu) 作为一个cuproptosis诱导剂.
- 检查了NFE2L2-GSH-SLC25A39通路,包括GCLM,GCLC和SLC25A39.
- 在细胞培养和小鼠模型中通过遗传抑制评估瘤抑制.
主要成果:
- 谷氨酸 (GSH) 被确定为胰腺癌细胞中cuproptosis的新型抑制剂.
- GSH 化铜以抑制质死,这与其在铁质死中的作用不同.
- 发现NFE2L2-GSH-SLC25A39通路对于GSH合成和线粒体进口至关重要,可以调节cuproptosis.
- 这种途径的遗传干扰增强了cuproptosis诱导的瘤抑制.
结论:
- 揭示了谷氨在抑制cuproptosis和ferroptosis的独特机制.
- NFE2L2-GSH-SLC25A39通路代表了胰腺癌的潜在治疗标.
- 针对这种途径的组合疗法可能为PDAC治疗提供一种新的策略.
更多相关视频
04:01Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics
Published on: March 15, 2024
08:22A Novel Strategy Combining Array-CGH, Whole-exome Sequencing and In Utero Electroporation in Rodents to Identify Causative Genes for Brain Malformations
Published on: December 1, 2017
相关概念视频
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Energy to Drive Translocation
Generally, polypeptides are unfolded by two distinct...
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Role of Reduced Coenzymes NADH and FADH₂
Regulation of Nuclear Protein Sorting
Nuclear Export
NES are of three types- the canonical 10-residue long leucine-rich signal and other...
